Halozyme Therapeutics Shares Popped: What You Need to Know (BAX, HALO, VPHM)

Halozyme Therapeutics Shares Popped: What You Need to Know

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of biotech Halozyme Therapeutics (Nasdaq: HALO ) soared close to 19% before closing up 6%. Licensing payments from ViroPharma (Nasdaq: VPHM ) and Baxter International (NYSE: BAX ) helped the company blow past second-quarter estimates.

So what: Revenue improved more than sevenfold to $23.2 million, with $18 million of that coming in upfront payments made by ViroPharma and Intrexon. Profits zoomed to $0.03 a share, reversing last year's $0.13 loss. Analysts were expecting a $0.13 loss on $4.95 million in revenue, according to data compiled by Yahoo! Finance.

Now what: Clearly there's momentum here, but the growth story could also be just beginning. Should ViroPharma like and broadly adopt Halozyme's enzyme technology, tens of millions more in milestone payments could lead to healthy gains for investors. Do you believe that's a likely outcome? Do you doubt it? Weigh in using the comments box below.

Interested in more info on Halozyme Therapeutics?Add it to your watchlist.

Jeff Fischer and team have demystified options. And they can rack up income like $1,030... $2,626... and $3,228 on a schedule you can set your watch by!
That's why we're glad to announce every single one of their closely guarded strategies is available to YOU during May and June – 100% FREE, no strings attached! Just enter your email address in the box below...

Fool contributorTim Beyers is a member of theMotley Fool Rule Breakers stock-picking team. He didn't own shares in any of the companies mentioned in this article at the time of publication. Check out Tim'sportfolio holdings andFoolish writings, or connect with him on Google+ or Twitter, where he goes by @milehighfool. You can also get his insightsdelivered directly to your RSS reader.

Try any of our Foolish newsletter servicesfree for 30 days. We Fools don't all hold the same opinions, but we all believe thatconsidering a diverse range of insights makes us better investors. The Motley Fool has adisclosure policy.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.

updated 1 day ago Sponsored by:
	DOW	15,303.10	8.60	0.06%
	S&P 500	1,649.60	-0.91	-0.06%
	NASD	3,459.14	-0.28	-0.01%

VPHM	$27.04		+0.60	+2.27%
ViroPharma, Inc.		CAPS Rating:

HALO	$7.42		-0.03	-0.40%
Halozyme Therapeut…		CAPS Rating:

BAX	$71.51		-0.64	-0.89%
Baxter Internation…		CAPS Rating:

0

Halozyme Therapeutics Shares Popped: What You Need to Know

Don't let it get away!

Comments from our Foolish Readers

Be the first one to comment on this article.

Compare Brokers

Report This Comment

Sending report...

Today's Market

Create My Watchlist

You don't seem to be following any stocks yet!

Related Tickers